2016年6月24-25日，临床肿瘤学新进展学术研讨会——Best of ASCO Event in China 2016在杭州召开。25日上午的肺癌专场上，解放军第307医院全军肿瘤中心肺部肿瘤科教授、中国抗癌协会化疗专业委员会委员刘晓晴对三项肺癌的重要研究进行评述。

三项研究摘要编号和题目：

Abstract 9008

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.

Abstract LBA8505

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer

(SCLC).

Abstract 8500

Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.

直通车：周清教授分享三项肺癌重要研究

会议专题》》》2016临床肿瘤学新进展学术研讨会（BOA）